Drugs.com - New Drug Approvals

FDA Approves Crenessity (crinecerfont) for the Treatment of Children and Adults with Classic Congenital Adrenal Hyperplasia

SAN DIEGO, Dec. 13, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved Crenessity (crinecerfont) capsules and oral solution as an adjunctive treatment to glucocorticoid...

Feb 9, 2025 - 22:25
 0
FDA Approves Crenessity (crinecerfont) for the Treatment of Children and Adults with Classic Congenital Adrenal Hyperplasia
SAN DIEGO, Dec. 13, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved Crenessity (crinecerfont) capsules and oral solution as an adjunctive treatment to glucocorticoid...
Read More

Tags:

Previous Article

Galderma Receives U.S. FDA Approval for Nemluvio (nemolizumab) for Patients with...

Next Article

FDA Approves Unloxcyt (cosibelimab-ipdl) for the Treatment of Cutaneous Squamous...

Related Posts

FDA Approves Lilly's Omvoh (mirikizumab-mrkz) for Crohn's Disease, Expanding Its Use to the Second Major Type of Inflammatory Bowel Disease

FDA Approves Lilly's Omvoh (mirikizumab-mrkz) for Crohn...

Feb 9, 2025  0

FDA Approves Tryngolza (olezarsen) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome

FDA Approves Tryngolza (olezarsen) to Reduce Triglyceri...

Feb 9, 2025  0

FDA Approves Steqeyma (ustekinumab-stba), a Biosimilar to Stelara

FDA Approves Steqeyma (ustekinumab-stba), a Biosimilar ...

Feb 9, 2025  0